Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Puxitatug Samrotecan in Advanced Adenoid Cystic Carcinoma
NCT07162480Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of puxitatug samrotecan in adenoid cystic carcinoma (ACC), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2026; status: recruiting.
02
Drugs
puxitatug samrotecan
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT07162480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07162480.